Sarepta Therapeutics (SRPT) Prepaid Assets (2010 - 2026)
Sarepta Therapeutics (SRPT) posted Prepaid Assets of $105.8 million for Q2 2026, down 43.72% on a QoQ basis from $188.0 million in Q1 2026, and down 17.09% year-over-year from $127.6 million in Q2 2025.
Analysis
Sarepta Therapeutics (SRPT) Prepaid Assets (2010 - 2026) Analysis & Trends
Sarepta Therapeutics has reported Prepaid Assets for 17 years, with the latest figure at $105.8 million in Q2 2026.
- On a quarterly basis, Prepaid Assets fell 17.09% year-over-year to $105.8 million in Q2 2026; TTM through Jun 2026 was $105.8 million, a 17.09% decrease from a year earlier, with the FY2025 full-year figure at $171.9 million, up 89.98% from the prior year.
- Prepaid Assets was $105.8 million for Q2 2026 at Sarepta Therapeutics, down from $188.0 million in the prior quarter.
- The five-year high for Prepaid Assets was $192.3 million in Q3 2025, with the low at $74.7 million in Q2 2024.
- Average Prepaid Assets over 5 years is $134.2 million, with a median of $135.5 million recorded in 2022.
- The sharpest annual moves came in 2024 and 2025: Prepaid Assets tumbled 53.85% in 2024, then soared 89.98% in 2025.
- Over 5 years, Prepaid Assets stood at $149.9 million in 2022, then plunged by 48.15% to $77.7 million in 2023, then gained by 16.4% to $90.5 million in 2024, then jumped by 89.98% to $171.9 million in 2025, then sank by 38.45% to $105.8 million in 2026.
- The last three Prepaid Assets figures came in at $105.8 million (Q2 2026), $188.0 million (Q1 2026), and $171.9 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn |
| 10 | Taysha Gene Therapies | 1.82 Bn | 1.82 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 105.78 Mn |
| Mar 31, 2026 | 187.97 Mn |
| Dec 31, 2025 | 171.86 Mn |
| Sep 30, 2025 | 192.35 Mn |
| Jun 30, 2025 | 127.59 Mn |
| Mar 31, 2025 | 105.48 Mn |
| Dec 31, 2024 | 90.46 Mn |
| Sep 30, 2024 | 165.48 Mn |
| Jun 30, 2024 | 74.74 Mn |
| Mar 31, 2024 | 82.97 Mn |
| Dec 31, 2023 | 77.71 Mn |
| Sep 30, 2023 | 154.44 Mn |
| Jun 30, 2023 | 148.22 Mn |
| Mar 31, 2023 | 179.77 Mn |
| Dec 31, 2022 | 149.89 Mn |
| Sep 30, 2022 | 130.74 Mn |
| Jun 30, 2022 | 129.33 Mn |
| Mar 31, 2022 | 140.33 Mn |
| Dec 31, 2021 | 149.03 Mn |
| Sep 30, 2021 | 147.94 Mn |